Burzynski Research Institute, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended August 31, 2023
October 12, 2023 at 04:15 pm EDT
Share
Burzynski Research Institute, Inc. reported earnings results for the second quarter and six months ended August 31, 2023. For the second quarter, the company reported net loss was USD 0.252104 million compared to USD 0.215918 million a year ago.
For the six months, net loss was USD 0.539509 million compared to USD 0.447655 million a year ago.
Burzynski Research Institute, Inc. is engaged in the research, production, marketing, promotion and sale of certain medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives and organic acids, which are known under the trade name Antineoplastons. Antineoplastons are useful in the treatment of human cancer and is reviewing data from its Phase II clinical trials of Antineoplastons relating to the treatment of various cancers. Antineoplastons are found in the bodily fluids of humans and food. The Company conducted all the Phase II clinical trials for the treatment of a variety of cancers using the combination of Antineoplastons A10 and AS2-1. Most of the trials involve the use of intravenous formulations of Antineoplastons; however, a few trials use oral formulations. The Company has not generated any operating revenue since its inception. The Company's clinical trials are conducted at the Burzynski Clinic.
BURZYNSKI RESEARCH INSTITUTE, INC. 
